Mayo Clinic Laboratories > Neurology > Peripheral neuropathy

Peripheral neuropathy

Patient Spotlight An uncommon antibody, a life restored: Jori Pearson

Expert-backed testing to establish diagnosis 

Lab testing is a powerful tool to assist physicians in identifying the causes of a patient’s peripheral neuropathy symptoms. Mayo Clinic Laboratories offers testing to identify peripheral autoimmune neuropathy with axonal or demyelinating causes, as well as next-generation sequencing (NGS) to help establish whether a peripheral neuropathy is genetic in nature.

Autoimmune peripheral neuropathy Autoimmune peripheral neuropathy
Autoimmune peripheral neuropathy

Our biomarker evaluations differentiate between peripheral autoimmune neuropathies that have either axonal or demyelinating causes. Treatment response differs depending on the underlying cause, and our expert-backed evaluations provide accurate results that set patients on the best treatment path.

Hereditary peripheral neuropathy Hereditary peripheral neuropathy
Hereditary peripheral neuropathy

Our hereditary peripheral neuropathy test menu includes both comprehensive and targeted NGS panels to assist in identifying genetic causes across the spectrum of peripheral neuropathies. A specific genetic diagnosis directly informs prognosis and impacts appropriate treatment and management, including use of gene-specific therapies.

News and updates

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Learn more
Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D.

Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide treatment decisions. Often misdiagnosed, CIDP is treatable if detected early.

Small Fiber Neuropathy: Diagnosis and Treatment

This “Specialty Testing” webinar will discuss the considerations physicians must weigh when evaluating suspected neuropathy patients with special emphasis put on small-fiber neuropathy and the most appropriate laboratory testing related to that phenotype.

Autoimmune Axonal Evaluation

Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on etiology, prognosis, and treatment choices.

MAG Antibody Testing [Test in Focus]

John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat condition known as DADS neuropathy.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.